Engineered Protein Inhibitors of SARS-CoV-2 Entry: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Shea Bailey (talk | contribs) No edit summary |
No edit summary |
||
| Line 52: | Line 52: | ||
[[Image:KdValues.jpg|400 px|right|thumb|Figure 5: The binding affinity values (Kd) and the half maximum inhibitory concentration values (IC50) are shown for ACE2, AHB2, LCB1 and LCB3<ref name="Cao">DOI:10.1126/science.abd9909</ref>.]] | [[Image:KdValues.jpg|400 px|right|thumb|Figure 5: The binding affinity values (Kd) and the half maximum inhibitory concentration values (IC50) are shown for ACE2, AHB2, LCB1 and LCB3<ref name="Cao">DOI:10.1126/science.abd9909</ref>.]] | ||
All three inhibitors show more advantages as a vaccine compared to antibodies due to their small size, stability and their ability to be quickly modified <ref name="Cao">DOI:10.1126/science.abd9909</ref>. | |||
</StructureSection> | </StructureSection> | ||
